Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46

Rhea-AI Filing Summary

Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.

The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mandel-Brehm Josh

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	580,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 580,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 580,000 shares Exercise price: $4.46 per share Expiration date: March 31, 2036 +3 more

6 metrics

Option grant size 580,000 shares Stock Option (Right to Buy) granted to CEO on April 1, 2026

Exercise price $4.46 per share Conversion or exercise price of stock option

Expiration date March 31, 2036 Option expiration for CEO stock option grant

Underlying common shares 580,000 shares Common Stock underlying the granted stock option

Post-grant option holdings 580,000 options Total stock options held directly by CEO after transaction

Vesting schedule 4 years monthly Vests in equal monthly installments over four years from grant date

Key Terms

Stock Option (Right to Buy), conversion or exercise price, expiration date, Common Stock, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 4.4600"

expiration date financial

"expiration_date: 2036-03-31T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest in equal monthly installments financial

"The shares underlying the option vest in equal monthly installments over a period of four years"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mandel-Brehm Josh

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.46	04/01/2026		A		580,000		(1)	03/31/2036	Common Stock	580,000	$0	580,000	D

Explanation of Responses:

1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.

Remarks:

	/s/ Josh Mandel-Brehm	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Camp4 Therapeutics (CAMP) disclose about Josh Mandel-Brehm’s equity award?

Camp4 Therapeutics disclosed that CEO Josh Mandel-Brehm received a stock option grant for 580,000 shares of Common Stock. The options have a $4.46 exercise price and expire on March 31, 2036, forming part of his long-term equity compensation.

How many Camp4 Therapeutics (CAMP) options were granted to the CEO?

Josh Mandel-Brehm was granted stock options covering 580,000 shares of Camp4 Therapeutics Common Stock. This entire amount is reflected as held directly after the grant, indicating a new equity-based incentive aligned with the company’s long-term performance.

What is the exercise price and term of the CAMP CEO’s stock options?

The CEO’s stock options have a $4.46 per share exercise price and expire on March 31, 2036. This means he can choose to purchase shares at $4.46 any time before that expiration date, once the options have vested.

How do Josh Mandel-Brehm’s Camp4 Therapeutics options vest over time?

The options granted to Josh Mandel-Brehm vest in equal monthly installments over four years from the grant date. This structure rewards continued service, as more of the 580,000 underlying shares become exercisable each month across the four-year period.

Did the Camp4 Therapeutics (CAMP) CEO buy or sell any common stock in this filing?

The filing shows a grant of stock options, not an open-market stock purchase or sale. It records an acquisition of derivative securities (options) as compensation, with no reported buying or selling of Camp4 Therapeutics Common Stock in the market.